Charles River Laboratories International, Inc. (NYSE:CRL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have received a consensus rating of “Moderate Buy” from the sixteen research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $211.00.

Several equities research analysts recently commented on the stock. Barclays boosted their price target on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Royal Bank Of Canada assumed coverage on shares of Charles River Laboratories International in a report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 price target for the company. Weiss Ratings lowered shares of Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th. Robert W. Baird set a $213.00 target price on shares of Charles River Laboratories International in a report on Friday, May 8th. Finally, CLSA raised shares of Charles River Laboratories International from a “hold” rating to an “outperform” rating and upped their target price for the stock from $167.00 to $219.00 in a report on Friday, May 29th.

Institutional Investors Weigh In On Charles River Laboratories International

A number of large investors have recently modified their holdings of the business. Tema Etfs LLC acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth about $26,000. Los Angeles Capital Management LLC purchased a new stake in shares of Charles River Laboratories International during the fourth quarter worth approximately $42,000. Sfam LLC acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth $43,000. Activest Wealth Management lifted its holdings in shares of Charles River Laboratories International by 10,900.0% during the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after purchasing an additional 218 shares during the period. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after purchasing an additional 145 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $185.17 on Monday. The firm has a market cap of $8.92 billion, a PE ratio of -49.25, a PEG ratio of 2.12 and a beta of 1.46. The firm has a fifty day moving average of $174.82 and a 200 day moving average of $182.75. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. Charles River Laboratories International has a one year low of $144.26 and a one year high of $228.88.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.96 by $0.10. The company had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm’s revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, research analysts predict that Charles River Laboratories International will post 11.04 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.